These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33788389)

  • 21. A Pediatric Case of B Cell Precursor ALL With Blinatumomab-associated Encephalopathy.
    Shimomura M; Tanaka M; Kobayashi Y; Izumo H; Tateishi Y; Mizoguchi Y; Kawaguchi H; Okada S; Karakawa S
    J Pediatr Hematol Oncol; 2024 Oct; 46(7):e550-e555. PubMed ID: 39008535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma.
    Ivanov V; Farnault L; Mercier C; Colavolpe C; Venton G; Colle J; Lepidi H; Arnoux I; Nicolino-Brunet C; Berda-Haddad Y; Fanciullino R; Ivanov G; Costello R
    Leuk Lymphoma; 2020 May; 61(5):1230-1233. PubMed ID: 31900013
    [No Abstract]   [Full Text] [Related]  

  • 23. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gore L; Locatelli F; Zugmaier G; Handgretinger R; O'Brien MM; Bader P; Bhojwani D; Schlegel PG; Tuglus CA; von Stackelberg A
    Blood Cancer J; 2018 Aug; 8(9):80. PubMed ID: 30190453
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.
    Jabbour E; Patel K; Jain N; Duose D; Luthra R; Short NJ; Zugmaier G; San Lucas A; Velasco K; Tran Q; Zaman F; Konopleva M; Kantarjian H
    Am J Hematol; 2021 Oct; 96(10):E379-E383. PubMed ID: 34161631
    [No Abstract]   [Full Text] [Related]  

  • 25. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
    Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
    N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
    Kawakami Y; Imamura M; Imai C
    Int J Hematol; 2024 May; 119(5):479-480. PubMed ID: 38492197
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
    Marini BL; Sun Y; Burke PW; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinatumomab: first global approval.
    Sanford M
    Drugs; 2015 Feb; 75(3):321-7. PubMed ID: 25637301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC; Gökbuget N
    Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Whitlock JA; Peters C; Chen-Santel C; Chia V; Dennis RM; Heym KM; Katz AJ; Kelsh MA; Sposto R; Tu H; Tuglus CA; Verma A; Vinti L; Wilkes JJ; Zubarovskaja N; Zugmaier G; von Stackelberg A; Sun W
    Leukemia; 2020 Sep; 34(9):2473-2478. PubMed ID: 32094465
    [No Abstract]   [Full Text] [Related]  

  • 33. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett T; Duell J; Bargou RC; Holland C; Benjamin JE; Klinger M; Litzow MR
    Leukemia; 2018 Feb; 32(2):562-565. PubMed ID: 28990581
    [No Abstract]   [Full Text] [Related]  

  • 34. Comment on: Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
    Srinivasan S; Roy Moulik N; Dhamne C
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29874. PubMed ID: 35735751
    [No Abstract]   [Full Text] [Related]  

  • 35. Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Yeoh DK; Blyth CC; Kotecha RS
    Br J Haematol; 2022 Sep; 198(5):887-892. PubMed ID: 35727917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.